Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
Related Questions
Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per OncoType, but met NATALEE inclusion criteria?
In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?
Does delay to the time of lumpectomy impact your decision to omit radiation?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?
Do you make dose modifications to KEYNOTE-522 regimen in the elderly?
Is there data supporting the extension of adjuvant olaparib beyond one year in patients with early-stage HER2-negative breast cancer and germline BRCA1/2 mutations?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
What additional risk features, if any, would sway you to offer chemotherapy in premenopausal women with ER+ HER2- node positive patients whose Oncotype is < 11?
